Management of Renal Disease
Summary
- Cobicistat[FDA Cobicistat] and dolutegravir[FDA Dolutegravir] are each associated with serum creatinine increase that does not reflect changes in kidney function
- Before starting either agent or their combinations, measure creatinine levels at baseline, after approximately 1 month on therapy, with the on-treatment level regarded as patient’s new “baseline” value
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Renal Complications, Treatment Complications